ClinicalTrials.Veeva

Menu

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

U

University of Chinese Academy Sciences

Status

Enrolling

Conditions

PET/MR
Nasopharyngeal Carcinoma

Treatments

Diagnostic Test: PET/MR

Study type

Interventional

Funder types

Other

Identifiers

NCT03657017
PET/MR-2018-01

Details and patient eligibility

About

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

Enrollment

150 estimated patients

Sex

All

Ages

Under 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with newly histologically confirmed non-keratinizing carcinoma.
  • Tumor staged T1-4N0-3M0 (according to the 8th AJCC staging system)
  • Performance status: KPS>70
  • With normal liver function test (ALT, AST <1.5ULN)
  • Renal: creatinine clearance >60ml/min
  • Without hematopathy,marrow: WBC >4*109/L, HGB>80G/L, and PLT>100*109/L.
  • Written informed consent

Exclusion criteria

  • Adenocarcinoma
  • Age >70
  • Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin)
  • Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)
  • Patient is pregnant or lactating
  • Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), or emotional disturbance.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

150 participants in 1 patient group

PET/MR
Other group
Description:
Patients are examined with PET/MR.
Treatment:
Diagnostic Test: PET/MR

Trial contacts and locations

1

Loading...

Central trial contact

Caineng Cao, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems